Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.15%
#3 OpenEden OpenEden +11.48%
#4 BasedHype BasedHype +11.14%
#5 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#7 Mantle Staked Ether Mantle Staked Ether +8.34%
#8 Mantle Restaked ETH Mantle Restaked ETH +8.01%
#9 MarsCoin MarsCoin +6.65%
#10 EfficientFrontier EfficientFrontier +4.93%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
BioSyntech, Inc. BioSyntech, Inc.

BioSyntech, Inc.

BSYI
Classement en actions #40152
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels... BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology to precisely deliver biotherapeutics. Its technological assets also include Arthro-BST, an arthroscopic device for the non-destructive evaluation of cartilage degradation or repair, and Mach-1, a micromechanical testing system for assessing the properties of various tissues and materials. The company also manufactures ultra-pure chitosans under the Ultrasan brand and offers both manufacturing and analytical services. Founded in 1994 and based in Laval, Canada, BioSyntech Inc. initiated administration proceedings under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently undergoing reorganization.
Prix de l'action
$0.00001
Dernière synchronisation: 2025-09-24
Capitalisation boursière
$229.03K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
CA
Échange BioSyntech, Inc. (BSYI)

Catégorie

Healthcare
Revenus pour BioSyntech, Inc. (BSYI)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de BioSyntech, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour BioSyntech, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE